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In Brief
Using a large pan-cancer cohort, RubioPerez et al. develop an in silico drug prescription strategy based on driver alterations in each tumor and their druggability options and use it to identify druggable targets and promising repurposing opportunities.
INTRODUCTION
Recent advances in DNA sequencing technologies provide unprecedented capacity to comprehensively identify the alterations, genes, and pathways involved in the tumorigenic process, raising the hope of extending targeted therapies against the drivers of cancer from a few successful examples to a broader personalized medicine strategy (Garraway and Lander, 2013; Stratton, 2011) . However, large-scale studies confronted with the high degree of inter-tumor heterogeneity have uncovered long catalogs of cancer driver genes (Davoli et al., 2013; Kandoth et al., 2013; Lawrence et al., 2014; Tamborero et al., 2013a; Vogelstein et al., 2013) . The goal of using a tailored approach to treat all tumor patients may thus require developing a vast arsenal of anticancer targeted drugs. In addition, advances in our ability to precisely assign the most effective targeted therapy to each patient based on the genomic events driving the tumor are urgently needed. The present study offers a comprehensive assessment of the potential scope of targeted drugs in a large pan-cancer cohort. To pursue this goal, we developed a three-step in silico drug prescription strategy (Figure 1) , which included identifying the driver events acting across the cohort, collecting all therapeutic agents targeting them, and connecting each patient to all targeted therapies that could benefit them, thus producing a landscape of the scope of targeted therapeutic agents in the cohort.
Significance
The development of therapies targeting altered driver proteins holds the promise of selectively and efficiently eliminating cancer cells. Nevertheless, the extent of applicability of available anticancer targeted agents is unclear. Exploiting a large pan-cancer therapeutic landscape covering 6,792 tumors, we found that the prescription of approved therapeutic agents following their clinical guidelines could provide treatment only to a small fraction of tumor patients. Nevertheless, we also uncovered promising repurposing opportunities and found that agents in clinical trials could benefit an important fraction of cancer patients upon approval. Furthermore, we identified additional target genes for therapeutic development.
RESULTS
Step 1: Identifying Genes Driving Tumorigenesis in 28 Cancer Types The first step of the personalized in silico drug prescription strategy consists in identifying all the alterations driving tumorigenesis in a patients' tumor. To implement this step, we first collected and analyzed somatic mutations (single-nucleotide variants and short insertions and deletions), copy-number alterations (CNAs), fusion genes, and RNA sequencing (RNA-seq) expression data in 4,068 tumors of 16 The Cancer Genome Atlas (TCGA) studies, representing the same number of tumor types (hereafter, named core cohort). In addition, we collected somatic mutations for 2,724 additional tumors included in 32 exome sequencing studies covering 28 cancer types.
The following six sections of results describe this catalog of cancer driver genes in each tumor type-totaling 475 genes that drive tumorigenesis via mutations, CNAs or gene fusions-as well as their mode of action and whether their driver mutations are present in the majority of the tumor clonal population. All this information integrates the Cancer Drivers Database, available to researchers via our IntOGen web discovery platform (http://www.intogen.org; Gonzalez-Perez et al., 2013a) .
We Detect 459 Mutational Driver Genes in the 6792 Tumors of the Entire Cohort
The identification of mutational drivers is challenging due to both the high heterogeneity in the pattern of somatic mutations observed across tumor samples and the long tail of cancer genes mutated at very low frequency. We applied three methods The first step consists of identifying genomic driver events acting in the tumor cohort.
Step two involves finding the drugs targeting the driver protein products, and step three uses the generated information to in silico prescribe drugs to patients on the basis of their genomic driver events. This approach, applied to all patients in the cohort, provides the therapeutic landscape of cancer drivers shown in the middle panel. of analysis designed to detect complementary signals of positive selection in the pattern of somatic mutations in genes across samples (Gonzalez-Perez and Lopez-Bigas, 2012; Lawrence et al., 2013; Tamborero et al., 2013b) . The assumption is that mutations in certain genes provide a selective advantage to tumor cells that subsequently grow and proliferate faster; tracing the signals left by the selection across a cohort of tumors identifies the genes driving tumorigenesis . Furthermore, the combination of methods detecting complementary positive selection signals produces a more comprehensive and reliable list of cancer drivers . In the 48 cohorts under analysis (Table S1 , part A), we identified 459 mutational cancer driver genes acting in one or more tumor types, supporting recent reports that many new cancer genes are yet to be identified (Lawrence et al., 2014; Vogelstein et al., 2013) (Figure 2A ). The list contains genes previously identified as cancer drivers (Davoli et al., 2013; Futreal et al., 2004; Kandoth et al., 2013; Lawrence et al., 2014; Tamborero et al., 2013a; Vogelstein et al., 2013) , as well as many novel driver candidates (Figures 2B, S1A, and S1B and Table S1 , part D), some of which have been previously linked to tumor emergence, progression or metastasis through an array of different alterations (e.g., NCOR2, MAP3K4, PIK3CB, HDAC9, and NEDD4L). All of the identified drivers behaved similarly in several features in which cancer genes are known to deviate from other genes, such as their abnormally high connectivity in interactions networks, significant enrichment for rare germline variants, and low baseline tolerance to germline variants with functional impact ( Figure S1C ). Most of these cancer drivers exhibit low mutational frequency in the cohort; 63% were mutated in less than 1% of samples (Table S1 , part B). Although some cancer genes drive tumorigenesis across several tumor types, others appear to be specific to certain malignancies (Figure 2, Table  S1 , part C). Conversely, the number of genes able to drive the tumorigenesis varies widely between tumor types, ranging from the long catalogs detected in cutaneous melanoma and breast carcinoma (250 and 184, respectively) to the short lists identified in pilocytic astrocytoma and acute lymphocytic leukemia (2 and 12, respectively) ( Figure 2A ).
A Quarter of Mutational Drivers Are Involved in Cell-Regulatory Mechanisms
Most of the identified cancer drivers are involved in well-known cancer pathways ( Figure 2B ) (Hanahan and Weinberg, 2011; Vogelstein et al., 2013) . Within manually selected modules of genes acting in the same biological pathway, these drivers tend to be mutated in a mutually exclusive pattern ( Figure S1D and the Supplemental Experimental Procedures). Interestingly, about 25% of the drivers participate in general cell-regulatory processes, which are emerging cancer pathways. Three types of such regulators are widely represented among cancer drivers: chromatin regulatory factors (CRFs), splicing and mRNA processing regulators (SMRs), and members of the ubiquitinmediated proteolysis system (UPSs). Furthermore, some of the cancer drivers belonging to these groups appear to be mutated at relatively high frequency, such as MLL2, PBRM1, and ARID1A among CRFs, SF3B1 and DDX3X among SMRs, and VHL and FBXW7 among UPSs. With the exception of PBRM1 and VHL, which are specifically linked to the oncogenic process in renal clear cell carcinoma, cancer genes of these three functional groups drive tumorigenesis in several malignancies ( Figure 2B ). Their role in malignant transformation is most likely mediated by the misregulation they cause in specific cancer genes that are directly linked to oncogenic processes (Brooks et al., 2014; Ferreira et al., 2013; Malhotra et al., 2010; Przychodzen et al., 2013; Romero and Sanchez-Cespedes, 2014) .
The Mode of Action of the 459 Mutational Driver Genes Driver mutations-and by extension the genes that bear themcan be classified into three groups: (1) loss of function (LoF), typically tumor-suppressor genes whose disrupted function favors tumorigenesis; (2) gain of function (GoF), typical of oncogenes that, when abnormally activated, provide an advantage to the cell; and (3) switch of function (SoF), which provides a new function to the encoded protein that promotes malignant transformation. Identifying the mode of action of drivers is crucial to exploring the opportunities to therapeutically target drivers because, in principle, only proteins with activating (Act) mutations (GoF plus SoF) can be directly targeted with molecules able to inhibit their function. In contrast, LoF genes should be targeted through other strategies, such as the inhibition of a functionally connected gene (Oza et al., 2011) , the restoration of their abolished function (Khoo et al., 2014) , and the induction of synthetic lethality like the paradigmatic PARP inhibition for tumors with BRCA1/2 mutations (Fong et al., 2009 ). We used a random forest classifier, OncodriveROLE, to identify the mode of action of cancer drivers (Schroeder et al., 2014) based on mutation and CNA gene patterns. We found that 169 (36.8%) of the 459 cancer drivers identified in our multi-tumor cohort are Act, while 207 (45%) are LoF. The pattern in the remaining 83 (18.1%) drivers was not clear enough to achieve unambiguous classification (Supplemental Experimental Procedures, Figure 3A , and Table S2, part A).
A Limited Number of Drivers Clonally Dominate the Tumors Not all driver genes are equally important in the course of tumorigenesis. Tumors may be more addicted to mutations in certain drivers, which provide basic capabilities to cancer cells-such as the evasion of apoptosis or uncontrolled proliferation-than See also Figure S1 and Table S1. to others, which render added capacities to the basic tumorigenic phenotype that allow them to further progress and migrate (Vogelstein et al., 2013) . We hypothesized that mutations in the former genes, which we call major cancer drivers, should dominate the clonal population of these tumors. We found that mutations in 73 of the driver genes were biased toward large clonal frequencies across one or more of the 16 tumor samples cohorts in which this analysis was possible ( Figure 3B and Table S2 , part B). Major cancer drivers should include both genes responsible for the onset of tumorigenesis and genes harboring mutations that confer such powerful growth advantages to tumor cells that, when sequenced, the clones containing them have outgrown the founder clone. Although many major cancer drivers (45) See also Figure S2 and Table S2. therefore annotated in the Cancer Gene Census (CGC), others are involved in core cellular regulatory processes related to more recently described cancer processes, such as CRFs, SMRs, and UPSs. Overall, these major cancer drivers, grouped in several functional modules, appear to alter few cellular pathways upon mutation ( Figure S2A ). These groups of genes therefore constitute interesting targets for anticancer therapies.
We Identify 38 Drivers Acting via CNAs or Fusions in the Core Cohort
To complete the landscape of driver genes acting in the cohort, we also considered those actionable drivers acting via amplifications, deletions, or gene fusions in the 4,068 tumor samples from 16 cancer types in which these data were available (i.e., the core cohort). In each of these datasets, we considered candidate CNA drivers: (1) mutational driver genes in the corresponding tumor type and (2) manually selected targeted genes located within recurrently amplified of deleted genomic segments identified by the GISTIC analysis of the corresponding tumor type (Mermel et al., 2011) . In both cases, we only considered as CNA drivers those genes that exhibited CNAs with coherent expression changes -i.e., overexpressed Act drivers and underexpressed LoF drivers (Supplemental Experimental Procedures). As a result, we identified 29 targeted genes putatively driving tumorigenesis in one or more of these malignancies either via amplification (15) or deletion (14) ( Figure 2C and Table S1 , part E). Nine of these genes were driving cancer exclusively via CNAs: AURKA, CCND2, CCND3, CCNE1, CDK6, CDKN2B, IGF1R, MDM2, and MDM4. Moreover, 20 other genes were also mutational drivers (i.e., PTEN and CDKN2A) ( Figure 2E ).
Finally, we collected a list of genes (ten) known to drive tumorigenesis upon fusions by manually curating the literature ( Figure 2D and Table S1 , part F). Only high reliable fusion events per sample for in-frame fusions of both partners were taken into account.
The Cancer Drivers Database Identifies Tumorigenic Alterations in 90% of Tumors
Ninety percent of the 4,068 tumor samples in the core cohort bear at least one driver alteration defined in the Cancer Drivers Database. Tumor samples in the core cohort contain a median of three driver events, although the number of events per sample differs widely across tumor types (Figures 3C). These figures are actually underestimated due to, among others, lowly recurrent drivers that remain unidentified at the current number of tumor re-sequenced genomes and unidentified driver non-coding mutations not assessed by exome-sequencing data, as well as other types of genomic or epigenomic alterations not considered in the present analysis. When only mutations are considered, the fraction of tumors with identified driver events drops from 90% to 86% in the core cohort and to 82% in the full cohort ( Figure S2B ).
Step 2: Collecting Drugs Targeting Driver Genes The second step of the in silico prescription strategy consisted in exhaustively searching for therapeutic options, either approved by the Food and Drug Administration (FDA) or in clinical or pre-clinical studies, to target mutational, CNA, and fusion driver genes detected in step one. We considered three different plausible approaches to target them: (1) inhibition of activated drivers with therapeutic molecules (direct targeting), such as Vemurafenib-targeting V600E-activating BRAF mutation; (2) inhibition of non-altered proteins functionally connected to the altered driver (indirect targeting), for example Temsirolimus, a MTOR inhibitor undergoing a clinical trial (Oza et al., 2011) to treat cancer patients bearing PTEN-inactivating mutations; and (3) gene therapies designed to compensate for the loss of activity of a tumor-suppressor driver. The process employed to identify these interactions and ancillary information relevant to their prescription to cancer patients, as well as its results, is described in the following two sections. All this information composes the Cancer Drivers Actionability Database (Supplemental Experimental Procedures) made available to researchers through IntOGen (http://www.intogen.org/downloads). Table S3 ). Seventy-four out of them were exclusively directly targeted, whereas 13 were only targeted indirectly; seven drivers could be targeted both directly and indirectly. We also found two gene therapies aimed at restoring the activity of two drivers ( Figure 4C ). Drivers targeted by agents following each of the three strategies with different levels of approval in the clinical practice are shown in Figure 4D . Finally, we found that 35 other drivers had a protein structure suitable for small molecule binding, named potentially druggable, and 26 could be accessed by antibody and protein therapies, named potentially biopharmable ( Figure 4A ).
Drugs Targeting Cancer Drivers
Of special interest in the catalog of targeted therapies are agents targeting multiple drivers, which could provide a wider therapeutic scope (Hopkins, 2008; Mestres et al., 2008) . We observed that 32 out of 57 (56.14%) FDA-approved drugs target multiple drivers (between 2 and 17), stressing the fact that a large proportion of cancer drugs are poorly selective. Multi-target options are likely to increase in the near future, as 23 therapeutic agents in clinical trials and 4,746 preclinical ligands target multiple drivers ( Figure S3 ).
Cancer Drivers Actionability Database
We complemented the list of therapeutic anticancer agents with ancillary information on their clinical use and the options for repurposing them and integrated all these data within the Cancer Drivers Actionability Database. The database contains information on the tumor type for which the drug is prescribed (for FDA-approved drugs) or is being tested (for drugs in clinical trials). It also contains rules that take into account the type of driver alteration considered actionable, according to clinical guidelines (e.g., Afatinib is clinically prescribed for the EGFR L858R mutation) and/or according to the specification in clinical trials or in the literature (e.g., Imatinib is being tested for PDGFRA mutations). Additionally, the database considers alterations known to be causative of drug primary resistances (e.g., KRAS mutations cause resistance to Cetuximab), according to clinical guidelines or clinical or pre-clinical investigations.
The database also defines rules for the possible expansions of the use of approved drugs in cancer treatment. In particular, we have considered six cases where the repurposing of FDAapproved drugs could prove useful. We stratified them in three tiers, according to their feasibility (Supplemental Experimental Procedures). Tier 1 includes (1) tumor type repurposing (tumor types different than the one considered in the clinical guidelines) and (2) disease repurposing (agents approved for other diseases that are however able to target cancer driver proteins). Tier 2 includes (1) alteration repurposing (agents targeting an alteration of a driver that could be employed in the event of another type of alteration of the same gene), (2) indirect targeting repurposing (agents that target a specific oncoprotein but have proven useful counteracting the alteration in another connected driver), and (3) strong off-target repurposing (agents that bind more potently than drug primary targets, the clinically intended ones). Tier 3 includes mild off-target repurposing (agents which bind to off targets with an affinity less potent than the one for their primary targets, but more potent than 1 mM). We have included in the database rules to filter out 12 known cases of repurposing that have rendered negative results in clinical trials (Table S4 , part B), obtained manually from the literature. Furthermore, we have collected information from 98 currently ongoing clinical trials that assay repurposing opportunities considered in our database, some of which have proven successful (Table S4 , part A).
Step 3: Connecting Targeted Therapeutic Agents to Patients The third step of the in silico prescription strategy consists in determining which targeted therapies could benefit a patient (Figure 1 ). To make this decision, we select the driver alterations in the tumor on the basis of the Cancer Drivers Database. Then, therapies are matched to those alterations taking into account the interactions and rules in the Cancer Drivers Actionability Database.
We applied this procedure to the 4,068 patients of the core cohort, taking into account the observed somatic mutations, CNAs, and fusion events (Table S4 , part D), and to the full cohort of 6,792 patients considering only somatic mutations (Table S4 , part C). The obtained therapeutic landscapes allowed us to answer (1) what fraction of the patients of these tumor types could benefit from currently available targeted therapies, (2) what fraction of them might benefit from targeted therapies currently under clinical trials or in pre-clinical stages, and (3) what fraction of them may receive multiple agents aimed at improving their response to therapy. The following five sections describe these targeted therapeutic landscapes and answer these questions.
Approved Targeted Therapies Could Benefit 5.9% of the Patients in the Core Cohort Of the 4,068 samples of the core cohort, only 241 are in silico-prescribed FDA-approved drugs following their primary indications. In other words, only 5.9% of the patients represented by this pan-cancer cohort could be treated with targeted therapies directed to modulate the activity of mutated, amplified, deleted, or fused driver proteins under current clinical guidelines ( Figure 5 ). All samples tractable with approved targeted approaches are concentrated in six tumor types: cutaneous melanoma, colorectal adenocarcinoma, head and neck squamous cell carcinoma, renal clear cell carcinoma, breast carcinoma, and acute myeloid leukemia ( Figure 6A ). Most of these (101) are breast carcinoma samples bearing ERBB2 amplifications, with in silico prescriptions for Lapatinib, Pertuzumab, and Trastuzumab ( Figure 6B) . See also Figure S3 and Table S3 .
When only drugs targeting mutational drivers in patients of the full cohort are considered ( Figure S4 ), there is a substantial decrease in the proportion of tumors susceptible of treatment with FDA-approved drugs according to clinical guidelines (2.9%). The contrast between these two results highlights the significance of exploring driver CNAs and fusions when making clinical decisions on cancer patients. In any case, the proportion of samples benefiting from FDA-approved drugs following clinical guidelines is still slim.
Drug Repurposing Increases up to 40.2% the Fraction of Patients that Could Benefit from FDA-Approved Drugs Drug repurposing is a promising strategy to maximize the benefits of currently available drugs (Gupta et al., 2013) . The in silico drug prescription procedure assigned FDA-approved drugs according to one or more of the repurposing strategies considered here to 1,635 patients of the core cohort (40.2%) ( Figure 5A ).
As mentioned above, tumor type repurposing was divided in three tiers according the feasibility of the therapy. Repurposing opportunities in tier 1 were mostly tumor type repurposing cases (835 out of the 838 patients benefiting from opportunities in the tier). Moreover, 697 of these patients could not benefit from approved drugs according guidelines ( Figure 5B ). Most of these opportunities were concentrated in three cancer types, amounting to 182 thyroid carcinoma, 168 glioblastoma, and 56 lung adenocarcinoma tumors (Figures 6A and 6B ). Kinase inhibitors represent the highest number of tumor type repurposing opportunities among all drug families, including cases of multiple in silico drug prescriptions for one tumor sample.
Repurposing opportunities in tier 2 could benefit 867 patients, out of which 587 could not be linked to more feasible therapies. FDA-approved drugs through indirect targeting repurposing were assigned to 692 patients. Most of these samples were colorectal (120), uterine carcinomas (112), and glioblastomas (99). Deletions and/or truncating mutations of PTEN (377 samples), NF1 (148), and APC (138) received the largest share of these indirect opportunities ( Figure 7A ). On the other hand, alteration repurposing opportunities were concentrated in glioblastoma patients (76). Most of these patients (70) could receive Lapatinib tosylate, prescribed for ERBB2 overexpression, to target EGFR mutations.
Lastly, repurposing opportunities in tier 3 could be beneficial for 1,153 patients, 110 of which could not be prescribed more feasible therapies. In summary, the fraction of samples benefiting from FDA-approved drugs prescribed in silico increases markedly (from 5.9% to 40.2%) if repurposing opportunities are considered, with important differences between tumor types ( Figure 6 ). Nevertheless, the usefulness of repurposing to treat cancer patients is slimmer if only somatic mutations are considered, from 2.9% to 24.7% in the full cohort ( Figure S4 ).
1,346, or 33.1% Further Patients in the Cohort Could Benefit from Drugs Currently Under Clinical Trials
When targeted therapies currently in clinical trials are also considered, the number of tractable tumors increases to 2,981 (73.3%) in the core cohort ( Figure 5 ). Among them, 1,672 samples were in silico-prescribed drugs in clinical trials directly targeting their driver genes, 1,254 were found susceptible of undergoing gene therapies correcting for the LoF of a tumorsuppressor gene, and 1,284 could receive drugs in clinical trials indirectly targeting their driver alterations ( Figure 6B ). The importance of these drugs will prove paramount to patients suffering from certain malignancies, such as lower-grade glioma, ovarian cancer, and head and neck carcinoma, 76.2%, 69.1%, and 55.6% of whom, respectively, could benefit from agents in clinical trials, but not from any other FDA-approved targeted therapies. These numbers are explained, to a great extent, by TP53 ( Figure 7B) , which is the subject of a gene therapy that can compensate for its LoF mutations (Buller et al., 2002) and is altered in 1,250 samples. The overall fraction of patients A B Figure 5 . Therapeutic Landscape of the Core Cohort Sets of patients susceptible of different types of interventions are shown both in their overlaps (A) and as non-overlapping groups following a hierarchy (B) (i.e., each patient is uniquely labeled in one category following the ordered hierarchy). The same classification for full cohort is available in Figure S4A . See also Table S4 . benefiting exclusively from drugs in clinical trials is almost equally significant in the full cohort (34.9%; Figure S4 ). Finally, 2,055 patients (50.5%) were assigned ligands currently in preclinical stages, and only 58 of them are not prescribed agents either in clinical guidelines or FDA approved; the tumors of 68 and 34 other patients have protein-affecting mutations in potentially druggable and biopharmable drivers, respectively ( Figure 5 ).
39% of Patients in the Core Cohort Could Receive Combination Therapies against Multiple Drivers
The combination of multiple agents is probably the most intuitive strategy to improve the efficacy of the response of tumors to treatment and to diminish their resistance to targeted therapies Pemovska et al., 2013) . The in silico drug prescription approach identified 1,598 patients (39%) of the core cohort with sets of altered drivers susceptible of being targeted with combinations of therapeutic agents both approved and undergoing clinical trials ( Figure 6C ). In other words, an important fraction of the patients in the cohort could benefit from existing or future combination therapies, although the majority of patients could currently only be prescribed a single targeted agent. The landscape of available combinatorial targeting strategies varies per tumor type ( Figure 6C ).
Polypharmacology could, in principle, achieve results similar to drug combinations targeting more than one altered driver in a tumor, without the potential problem of added toxicity. Sixtynine samples presented mutations in at least two drivers that could be simultaneously targeted by the same FDA-approved drug. Up to 451 (11.1%) patients would benefit from polypharmacology if the drugs in clinical trials are also considered. These results highlight the need to develop new and smarter anticancer therapies and strategies to expand the landscape of combination therapies.
Priority Gene Candidates for Drug Development
In our thorough survey of anticancer drugs and their targets, we detected 19 non-LoF drivers tightly bound by preclinical small molecules that are not currently targeted by any drugs that are FDA-approved or in clinical trials ( Figure 4A ). Moreover, 61 other non-LoF drivers present properties that make them potentially druggable or biopharmable (Figure 8 ). These 80 drivers are altered in 2,730 (67.1%) samples across the cohort. Interestingly, 63 of them are not well-established cancer genes (not included in the CGC). Six of them, bearing protein affecting mutations in 370 (5.4%) samples, are major drivers, a fact that makes them particularly promising as targets for drug development.
Focusing on the 25 drivers in this list that bear mutations in more than 5% of tumors of at least one cancer type, which constitute probably the first-line candidates for drug development, we discovered 13 cancer genes that are not well-established (Table  S5 describes ten of them in detail). At least four of these targets (SVEP1, PCDH18, PTPRU, and FAT2) function in biological processes related to cell adhesion and migration, while three others (KALRN, MACF1, and TRIO) modulate changes in the organization of the cytoskeleton. Another gene is involved in the regulation of cell cycle, TAF1, encodes one component of the transcription initiation complex and is thus essential for the progression of the cell cycle into G1. The possibility to develop therapeutic agents targeting cell-cycle mediators is exciting because most drivers affecting this process lose their function upon mutation. Other potentially actionable drivers encode a component of an ubiquitin-mediated proteolysis complex (SPOP), a cell membrane receptor involved in exocytosis (LPHN2), and an enzyme involved in the pyrimidine synthesis pathway (CAD) (Figure 8 ). CTNNB1 presents especially appealing opportunities to develop targeted therapeutic agents to treat an important fraction of the patients suffering from uterine carcinomas (28%) and medulloblastomas (12%), two tumor types with few currently available targeted therapeutic options.
DISCUSSION
The availability of the sequences of thousands of tumor genomes has raised the hope of being able to identify all cancer driver events that could be targeted by existing and novel drugs. This in turn is expected to extend targeted therapies from a few successful examples to a toolbox of tailored drugs that deliver the promise of personalized cancer medicine. In this work, exploiting one of the largest available tumor cohorts (6,792 samples), we sought to (1) determine the scope of applicability of anticancer targeted drugs and (2) propose ranked lists of genes to develop novel targeted drugs. Pursuing these goals, we devised an in silico prescription strategy of targeted therapeutic agents. The strategy includes the development of a Cancer Drivers Database, containing lists of genes driving tumorigenesis upon mutations, CNAs, and fusion events in different tumor types, and a Cancer Drivers Actionability Database, containing a comprehensive set of current and prospective anticancer targeted agents and sets of rules to prescribe them to patients. Connecting targeted agents to patients in the cohort, we obtained its therapeutic landscape as a snapshot in time, which will be improved with more updated Cancer Drivers Database and Cancer Drivers Actionability Database information as our knowledge of driver genes and anticancer therapies progress.
The analysis presented here has some limitations inherent to the nature of the data employed. The identification of driver genes is limited by three main hurdles. First, our analysis does not include non-coding mutations and methylation changes. Second, lowly recurrent drivers not well represented in the analyzed cohort remain unidentified. Third, the data employed to detect drivers may contain intrinsic errors, like those introduced by the calling of somatic mutations.
Also, we relied on proxy features to predict the mode of action of each driver as Act or LoF, with remarkably good results for the CGC; however, 83 drivers of our list could not be unambiguously classified, especially those whose mutations pattern could not be assessed due to their low frequency. Furthermore, we acknowledge that some genes exhibit divergent modes of action in different cancer types (Schroeder et al., 2014) .
The analysis of clonal frequency is limited by the use of lowcoverage sequencing data. These were suitable, however, to our endeavor of identifying major drivers, whose therapeutic intervention could exhibit a larger benefit. The analysis is based on detection of genes bearing mutations biased toward larger clonal frequencies across each tumor cohort, which is less sensitive to the accuracy of the data as compared to other analyses aimed to reconstruct the exact clonal architecture of each tumor.
Finally, due to the inevitable incompleteness of drug-target interaction databases, the results we present here are an underestimation of the actual number of targeted drivers (Mestres et al., 2008) .
Our in silico prescription approach, based solely on actionable alterations in drivers, should be treated as an approach to estimate the maximum applicability of direct targeted therapies in the patients represented in our cohort. The rationale presents five main limitations: (1) all coherent alterations in driver genes (protein affecting mutations, amplifications, deletions, and fusions) acting in the corresponding tumor type are considered driver events, although some may well be passengers; (2) intra-tumor heterogeneity in each individual sample is not taken into account for the prescription of drugs due to limitations of low coverage sequencing data, although it is conceivable that targeting subclonal driver events may have lower efficacy or even lead to paradoxical effects in some cases (McGranahan and Swanton, 2015) ; (3) the Cancer Drivers Actionability Database considers resistance biomarkers of targeted drugs, although this is limited by the current landscape of already known biomarkers of primary response; (4) although a set of known negative repurposing cases are eliminated by the in silico prescription algorithm, these are limited to published results of clinical trials; and (5) the approach does not take into account specificities pertaining to the mode of administration of each drug that may limit their repurposing opportunities.
Despite the aforementioned limitations, the approach presented here constitutes the proof of principle of a straightforward strategy to intelligently exploit cancer genome information to aid toward precise cancer medicine (Garraway, 2013) . This strategy, which combines a Cancer Drivers Database and a Cancer Drivers Actionability Database by means of an in silico prescription method, presents two unique features. First, our approach considers which alterations are drivers in each cancer type. It therefore diverges from other studies that start with a list of pre-defined cancer proteins and consider prescribing all drugs targeting their observed alteration regardless of their importance in the corresponding tumor type (Van Allen et al., 2014) . The intervention only on driver events avoids overprescription ( Figure S4D ). The information of all driver alterations in the study cohort, provided via the IntOGen resource (Gonzalez-Perez et al., 2013a), can be exploited for other purposes by the cancer research community, such as the support for interpretation of newly sequenced tumor genomes or the design of optimal sequencing panels.
Second, targeted therapies in the Cancer Drivers Actionability Database comprise manually curated anticancer drugs currently in use in the clinic or currently under clinical trials, as well as automatically retrieved ligands that bind to cancer genes and are candidates for prospective drug development. Another feature of this database is the explicitly defined rules that guide Figure S5B for the complete heatmap of the targeted genes. See also Figure S5 . THCA   UCEC   MACF1  FAT2  SVEP1  ROBO2  PCDH18  GNAS  COL1A1  PTCH1  CUX1  ZNF638  LRP6  EIF4G3  PLXNA11  PLXNB2  FCRL4  POM121  ZNF814  DLG1  NTN4  GOLGA5  NDRG1  RHOT1  ACSL3  CLCC1  ACAD8  WNT5A  CTNNB1  PCSK5  TRIO  ACACA  CAD  ADCY1  NEF2L2  PTPRF  BLM  PTPN11  PCSK6  AHR  XPO1  LNPEP  ADAM10  CARM11   ATF1  MGMT  MDM4  KALRN   F8  PLCB1  LPHN2  TAF1  WNK1  PTPRU  ARFGEF2  PRPF8  USP6  SOS1  NUP98  CNTNAP1  STARD13   DHX9  ARID4A  PLCG1  SPOP  PPP2R1A   ITGA9  NEDD4L  TNPO1  CAT  RHOA  PAX5  RAC1  TRIP10  NR2F2  NCK1  CAPN7  PIK3R3  PPP2R5C  ARFGAP1  MAT2A See also Table S5 .
the different types of repurposing. In these two respects, it is different from other existing resources that compile anticancer drugs and their interactions with cancer proteins (Van Allen et al., 2014; Halling-Brown et al., 2012) . The in silico drug prescription based on these two resources was tested on one of the largest cohorts of tumor samples currently collected for research. The main result highlights the current scope of targeted anticancer therapies and its prospects for growth in view of the drugs that are currently in clinical trials or at pre-clinical stages. The second important output of this work is a ranked list of additional target opportunities for anticancer drug development. Continuous update of drug-target interaction information, as well as the application of the strategy to larger cohorts, will improve the in silico prescription rules contained within the Cancer Drivers and Cancer Drivers Actionability Databases, thus enhancing its usefulness within personalized cancer medicine.
EXPERIMENTAL PROCEDURES Somatic Alterations Data
We obtained the lists of somatic mutations detected across tumor samples of 48 individual cohorts from three main sources: TCGA pan-cancer (Weinstein et al., 2013 ) (syn1710431 and syn300013), the ICGC Data Coordination Centre (Hudson et al., 2010) , and supplementary material of other published large cancer cohort publications. Details on all datasets are provided in Table S1 , part A. The datasets were filtered as previously published to eliminate possible false-positive somatic variants. Gene expression and copy-number data of the 16 TCGA cancer projects were obtained from the Synapse platform (syn300013).
Identification of Mutational Cancer Drivers
We searched for three complementary signals of positive selection in the mutational pattern of genes across the samples of each individual cohort of tumors and across the TCGA pan-cancer cohort. To that effect, we employed three methods designed to detect (1) abnormal accumulation of high-impact mutations across samples (OncodriveFM [Gonzalez-Perez and Lopez-Bigas, 2012] ), (2) abnormal clustering of mutations in regions of the protein sequences (OncodriveCLUST [Tamborero et al., 2013b] ), and (3) the recurrence of mutations above the background mutation rate (MutSigCV [Lawrence et al., 2013] ). The lists of genes identified by these methods were combined as described in Tamborero et al. (2013a) and the Supplemental Experimental Procedures to obtain the final list of mutational drivers acting in each tumor type.
Classification of Mutational Drivers According to their Mode of Action
We used OncodriveROLE (Schroeder et al., 2014) , a random forest classifierbased tool trained on several parameters related with the alteration pattern of genes across samples in the TCGA pan-cancer cohort, to predict whether driver genes act as LoF or activating (GoF/SoF) drivers. The training, test, and parameters employed in this classification are detailed in Schroeder et al. (2014) and the Supplemental Experimental Procedures.
Identification of Major Mutational Drivers
We took the ratio between the number of reads supporting the mutant and the reference alleles as an estimator of the variant allele frequency (VAF) of the mutation. Genes within amplified chromosomal segments were excluded since it is unknown to which extent they affect the mutant and wild-type allele counts. Several measurements were applied to correct the VAF values to take into account heterozygous deletions, copy-neutral loss-of-heterozygosity events, and differences in tumor purity between samples. We computed the observed trend of each driver to bear mutations with higher VAFs. We as considered major drivers of each tumor cohort those that exhibited a significant bias toward a higher VAF compared to other genes (Supplemental Experimental Procedures).
Identification of CNA and Fusion Drivers
To identify genes putatively driving tumorigenesis in TCGA cohorts via CNAs, we selected known cancer genes with targeted drugs found within recurrently altered segments according to GISTIC (Mermel et al., 2011) and genes identified as mutational drivers by the aforementioned analysis per each cohort. Only those LoF drivers exhibiting homozygous deletions and concomitant downregulation, and non-LoF drivers with multi-copy amplifications and that were upregulated, were included as putatively CNA drivers. LoF genes that appeared to be heterozygously deleted and mutated in the same sample were also included (Supplemental Experimental Procedures). In parallel, a list of genes known to cause malignization via fusions was manually retrieved from the literature. Then, we interrogated the TCGA Fusion Gene Data Portal (Yoshihara et al., 2014) to obtain a list of the samples exhibiting in-frame fusions of these genes with any partner in the core cohort (Supplemental Experimental Procedures).
All driver genes in each tumor type of the cohort (Supplemental Experimental Procedures), the evidence supporting their involvement in oncogenesis and their roles in malignization-and consequently the type of their somatic alterations relevant to treatment-and their relative importance within the clones making the tumor were collected into the Cancer Drivers Database.
Curation of Drug-Target Interactions
We considered three different targeting strategies: gene therapies and direct and indirect targeting. Moreover, we grouped therapeutic agents within the categories in FDA approved, agents in cancer clinical trials, and agents in cancer pre-clinical ligands.
Direct targeting interactions were mainly retrieved from ChEMBL (v18) (Gaulton et al., 2012) , a manually curated chemical database of bioactive molecules. We took into consideration all interactions with affinity above 1 mM. For FDA-approved drugs, we distinguished three different types of targets: primary (as specified in FDA label, according ChEMBL), strong off target (interacting more potently than the primary targets of the drug), and mild off target (more potent than 1 mM but less than the primary target). We also included some direct interactions from other sources (Supplemental Experimental Procedures). Indirect targeting candidates were mainly retrieved from the TARGET database (Van Allen et al., 2014) . However, interactions with molecules were obtained from literature, expert annotation, the drug's FDA label, or ClinicalTrials.gov (http://clinicaltrials.gov/). We also included indirect targeting of ligands by therapeutic agents targeting their receptors. Gene therapies were included from records in The Journal of Gene Medicine Clinical Trial site (Ginn et al., 2013) , a comprehensive source of information on worldwide gene therapy clinical trials.
Next we added information for the tumor type of clinical prescription (for FDA-approved drugs, manually curated) and the tumor type of study (for drugs in clinical trials). We incorporated rules that take into account specific genomic dependencies for targeting, according clinical guidelines and/or according clinical trials or literature, either in the targeted gene or others. Rules were retrieved by compiling information from FDA labels, ClinicalTrials.gov, and the literature. Additionally, we also considered biomarkers of primary resistance from Gene Drug Knowledge Database (Dienstmann et al., 2014) , either in the FDA label or in NCCN guidelines, clinical trials, or case reports. Moreover, we defined a set of rules to broaden the scope of application of FDA-approved drugs as different types of repurposing (see the Results). We manually searched the literature for negative and positive results of clinical trials essaying the repurposing of opportunities in tier 1 (Table S4) .
We also labeled genes as potentially druggable if they were likely to bind small molecules according to the structure of their protein products and as potentially biopharmable if they could be targeted with antibodies or protein therapy (Supplemental Experimental Procedures). All of the information on the three types of targeting strategies considered, the level of approval of each agent, their clinical guidelines, and the possibilities to broaden their scope of application were incorporated into the Cancer Drivers Actionability Database.
Connecting Therapeutic Agents to Patients
Patients in the cohort were connected to all targeted therapies susceptible of treating them. To do this, first we enumerated all relevant alterations-in a sample of the core cohort or mutations in a sample of the full cohort-affecting drivers of the tumor type of the sample, based on the information in the Cancer Drivers Database. Then, all targeted therapies suitable to treat each driver alteration in the sample were automatically retrieved from the Cancer Drivers Actionability Database, respecting the specific requirements defined for each therapeutic agent (of genomic alterations, tumor type prescription, and drug primary resistances). In the absence of such specific information, we connected the targeted drug to any relevant alteration of the target driver in the sample in question. 
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